Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).

Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, Brown PH.

Cancer Prev Res (Phila). 2019 Jul;12(7):481-490. doi: 10.1158/1940-6207.CAPR-18-0444. Epub 2019 May 28.

PMID:
31138522
2.

Improving attribution of adverse events in oncology clinical trials.

George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS.

Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Review.

PMID:
31108240
3.

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation.

Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME.

J Natl Cancer Inst. 2019 Mar 1;111(3):245-255. doi: 10.1093/jnci/djy221.

4.

Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM.

J Am Med Inform Assoc. 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169.

PMID:
30840079
5.

Long-Term Effects of Finasteride on Prostate Cancer Mortality.

Goodman PJ, Tangen CM, Darke AK, Lucia MS, Ford LG, Minasian LM, Parnes HL, LeBlanc ML, Thompson IM Jr.

N Engl J Med. 2019 Jan 24;380(4):393-394. doi: 10.1056/NEJMc1809961. No abstract available.

PMID:
30673548
6.

Racial/Ethnic Differences in Comprehension of Biospecimen Collection: a Nationwide University of Rochester Cancer Center NCI Community Oncology Research Program Study.

Asare M, Heckler CE, Culakova E, Kamen CS, Kleckner AS, Minasian LM, Wendler DS, Feige M, Weil CJ, Long J, Cole SK, Onitilo AA, Peppone LJ, Morrow GR, Janelsins MC.

J Cancer Educ. 2019 Jan 5. doi: 10.1007/s13187-018-1464-z. [Epub ahead of print]

PMID:
30612315
7.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS.

J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185.

8.

Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study.

Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, Palesh O, O'Mara AM, Minasian LM, Williams AM, Magnuson A, Geer J, Dakhil SR, Hopkins JO, Morrow GR.

J Clin Oncol. 2018 Sep 21:JCO2018786624. doi: 10.1200/JCO.2018.78.6624. [Epub ahead of print]

PMID:
30240328
9.

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, Schrag D.

J Clin Oncol. 2018 Sep 11:JCO2018788620. doi: 10.1200/JCO.2018.78.8620. [Epub ahead of print]

PMID:
30204536
10.

Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).

Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL.

Breast Cancer Res Treat. 2018 Dec;172(3):603-610. doi: 10.1007/s10549-018-4946-0. Epub 2018 Aug 29.

PMID:
30159789
11.

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD.

JAMA. 2018 Jul 10;320(2):167-176. doi: 10.1001/jama.2018.8907.

12.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL.

Cancer Epidemiol. 2018 Aug;55:117-122. doi: 10.1016/j.canep.2018.06.005. Epub 2018 Jun 21.

13.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

14.

Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials.

Minasian LM, Frazier AL, Sung L, O'Mara A, Kelaghan J, Chang KW, Krailo M, Pollock BH, Reaman G, Freyer DR.

Cancer Med. 2018 May 30. doi: 10.1002/cam4.1563. [Epub ahead of print]

15.

Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Samimi G, Trabert B, Duggan MA, Robinson JL, Coa KI, Waibel E, Garcia E, Minasian LM, Sherman ME.

Gynecol Oncol. 2018 Mar;148(3):515-520. doi: 10.1016/j.ygyno.2018.01.016.

16.

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).

Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS.

J Natl Cancer Inst. 2018 Jun 1;110(6):669-676. doi: 10.1093/jnci/djx259.

17.

What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.

Atkinson TM, Hay JL, Dueck AC, Mitchell SA, Mendoza TR, Rogak LJ, Minasian LM, Basch E.

J Pain Symptom Manage. 2018 Mar;55(3):e3-e6. doi: 10.1016/j.jpainsymman.2017.10.024. Epub 2017 Nov 10. No abstract available.

18.

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

Lee SM, Zhang Y, Minasian LM, Unger JM, Hershman DL.

Cancer Invest. 2017 Aug 9;35(7):484-489. doi: 10.1080/07357907.2017.1340479. Epub 2017 Jul 10.

PMID:
28692317
19.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O'Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):409-418. doi: 10.1016/j.ijrobp.2017.02.002. Epub 2017 Feb 10.

20.

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.

J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.

21.

Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?

Samimi G, Minasian LM.

Cancer. 2017 May 15;123(10):1699-1702. doi: 10.1002/cncr.30525. Epub 2017 Mar 23. No abstract available.

22.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D.

JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.

23.

Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables.

Chandwani KD, Zhao F, Morrow GR, Deshields TL, Minasian LM, Manola J, Fisch MJ.

J Pain Symptom Manage. 2017 Jun;53(6):988-998. doi: 10.1016/j.jpainsymman.2016.12.347. Epub 2017 Feb 6.

24.

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.

Mishkin G, Minasian LM, Kohn EC, Noone AM, Temkin SM.

Gynecol Oncol. 2016 Dec;143(3):611-616. doi: 10.1016/j.ygyno.2016.09.026. Epub 2016 Sep 30.

PMID:
27697287
25.

Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL.

J Natl Cancer Inst. 2016 Aug 26;108(12). pii: djw168. doi: 10.1093/jnci/djw168. Print 2016 Dec.

26.

Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.

Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL.

Trials. 2016 Aug 12;17:400. doi: 10.1186/s13063-016-1524-9.

27.

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.

Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J.

J Clin Oncol. 2016 Sep 1;34(25):3014-22. doi: 10.1200/JCO.2015.66.2346. Epub 2016 Jun 20.

28.

Reducing Overtreatment in Gynecologic Oncology: The Case for Less in Endometrial and Ovarian Cancer.

Temkin SM, Tanner EJ, Dewdney SB, Minasian LM.

Front Oncol. 2016 May 9;6:118. doi: 10.3389/fonc.2016.00118. eCollection 2016. Review.

29.

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM.

Cancer Prev Res (Phila). 2016 Sep;9(9):713-20. doi: 10.1158/1940-6207.CAPR-15-0384. Epub 2016 May 24. Review.

30.

Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress.

Guertin KA, Grant RK, Arnold KB, Burwell L, Hartline J, Goodman PJ, Minasian LM, Lippman SM, Klein E, Cassano PA.

Free Radic Biol Med. 2016 Jun;95:349-56. doi: 10.1016/j.freeradbiomed.2016.03.010. Epub 2016 Mar 22.

31.

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Minasian LM, Tangen CM, Wickerham DL.

Semin Oncol. 2015 Oct;42(5):748-63. doi: 10.1053/j.seminoncol.2015.07.006. Epub 2015 Jul 10. Review.

32.

Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement.

Ligibel JA, Alfano CM, Hershman D, Ballard RM, Bruinooge SS, Courneya KS, Daniels EC, Demark-Wahnefried W, Frank ES, Goodwin PJ, Irwin ML, Levit LA, McCaskill-Stevens W, Minasian LM, O'Rourke MA, Pierce JP, Stein KD, Thomson CA, Hudis CA.

J Clin Oncol. 2015 Nov 20;33(33):3961-7. doi: 10.1200/JCO.2015.63.1440. Epub 2015 Aug 31. Review.

33.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group.

JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

34.

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM.

J Clin Oncol. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4.

35.

A randomized controlled trial of vitamin E and selenium on rate of decline in lung function.

Cassano PA, Guertin KA, Kristal AR, Ritchie KE, Bertoia ML, Arnold KB, Crowley JJ, Hartline J, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Klein E.

Respir Res. 2015 Mar 11;16:35. doi: 10.1186/s12931-015-0195-5.

36.

Multilevel modeling and value of information in clinical trial decision support.

Cui Y, Murphy B, Gentilcore A, Sharma Y, Minasian LM, Kramer BS, Coates PM, Gohagan JK, Klenk J, Tidor B.

BMC Syst Biol. 2014 Dec 24;8:6. doi: 10.1186/s12918-014-0140-0.

37.

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.

38.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D.

J Natl Cancer Inst. 2014 Sep 29;106(9). pii: dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.

39.

Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial.

Christen WG, Glynn RJ, Gaziano JM, Darke AK, Crowley JJ, Goodman PJ, Lippman SM, Lad TE, Bearden JD, Goodman GE, Minasian LM, Thompson IM Jr, Blanke CD, Klein EA.

JAMA Ophthalmol. 2015 Jan;133(1):17-24. doi: 10.1001/jamaophthalmol.2014.3478.

40.

Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1638-48. doi: 10.1158/1055-9965.EPI-14-0202. Epub 2014 Jul 15.

41.

Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, Minasian LM, Denicoff AM, O'Mara AM, Fisch MJ, Chauhan C, Aaronson NK, Coens C, Bruner DW.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju129. doi: 10.1093/jnci/dju129. Print 2014 Jul. Review.

42.

Organizational and physician factors associated with patient enrollment in cancer clinical trials.

Jacobs SR, Weiner BJ, Reeve BB, Weinberger M, Minasian LM, Good MJ.

Clin Trials. 2014 Oct;11(5):565-75. doi: 10.1177/1740774514536000. Epub 2014 Jun 5.

43.

Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial.

Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1494-504. doi: 10.1158/1055-9965.EPI-14-0115. Epub 2014 Apr 14.

44.

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA.

J Natl Cancer Inst. 2014 Mar;106(3):djt456. doi: 10.1093/jnci/djt456. Epub 2014 Feb 22.

45.

Phase III prostate cancer chemoprevention trials.

Parnes HL, Brawley OW, Minasian LM, Ford LG.

Recent Results Cancer Res. 2014;202:73-7. doi: 10.1007/978-3-642-45195-9_9.

PMID:
24531780
46.

Long-term survival of participants in the prostate cancer prevention trial.

Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG.

N Engl J Med. 2013 Aug 15;369(7):603-10. doi: 10.1056/NEJMoa1215932.

47.

Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E; NCI PRO-CTCAE Study Group.

Qual Life Res. 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1. Epub 2013 Jul 20.

48.

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR.

J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41. doi: 10.1093/jnci/djt174. Epub 2013 Jul 10.

49.

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS.

J Clin Oncol. 2013 Jul 10;31(20):2627-33. doi: 10.1200/JCO.2012.44.8738. Epub 2013 Jun 3.

50.

A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment.

Reilly CM, Bruner DW, Mitchell SA, Minasian LM, Basch E, Dueck AC, Cella D, Reeve BB.

Support Care Cancer. 2013 Jun;21(6):1525-50. doi: 10.1007/s00520-012-1688-0. Epub 2013 Jan 12. Review.

Supplemental Content

Loading ...
Support Center